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Abstract [249/250 words] 
Background 
The PROTECT Benefit-risk group is dedicated to research in methods for continuous 
benefit-risk  monitoring of medicines, also including the presentation of the results, with a 
particular emphasis on graphical methods.1 
Methods 
A systematic review was performed to identify visuals used for medical risk, and 
benefit-risk communication. The identified visual displays were grouped into visual types, and each 
visual type was appraised based on five criteria: intended audience, intended message, knowledge 
required to understand visual, unintentional messages that may be derived from the visual and 
missing information that may be needed to understand the visual.  
Results 
66 examples of visual formats were identified from the literature and classified into 14 
generic visual types. We found that there is not one single visual format that is consistently superior 
to others for the communication of benefit-risk information, instead we found that most of the 
drawbacks found in the visual formats could be considered general to visual communication, 
although some appear more relevant to specific formats, and should be considered when creating 
visuals for different audiences depending on the exact message to be communicated.  
Conclusion 
We have arrived at recommendations on the use of visual displays for benefit-risk 
communication. The first recommendation refers to the creation of visuals. We outline four criteria 
to determine audience-visual compatibility and consider these to be a key task in creating any 
visual. Next we propose specific visual formats of interest, to be explored further for their ability to 
address nine different types of benefit-risk analysis information.    
 
  
Background 
This review was carried out as part the Innovative Medicine Initiative 
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (IMI 
PROTECT) project work package 5- Benefit-risk integration and representation (PROTECT BR 
group). PROTECT BR group is dedicated to research in methods for continuous benefit-risk (BR) 
monitoring of medicines, including both the underpinning modelling and the presentation of the 
results, with a particular emphasis on graphical methods.1 This literature review of visual 
representation and visual/graphical formats for BR communication followed a review of methods 
for medicinal BR assessment,2 both were used to provide input to the PROTECT BR group case 
studies exploring the utility of BR methods and visual formats for communication in connection to 
BR assessment.  
When communicating about BR it is important to be aware that we distinguish 
between efficacy and safety data on the one hand, and benefit and risk on the other requiring 
interpretation of the efficacy and safety data for their clinical and therapeutic relevance. Benefits are 
defined as favorable effects and risk as unfavorable effects, separate from the uncertainty of 
experiencing the effects.3 
Visual representation of BR information for decision-making of medicinal products is 
not completely exclusive to PROTECT BR group. We gained insight from other resources as a 
starting point for this review, including the recent BR Methodology Project commissioned by the 
European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) 
commissioned study to investigate the value of adding quantitative summaries of benefits and risks 
in standardised formats including visual displays and numerical formats4. More general initiatives 
visual representation of data and communication by special interest groups and individuals are 
available on the internet.5-14 
The aim of this review is to evaluate the usefulness of different visual types for the 
representation and communication of BR assessment information.  
Method 
Literature search strategy 
We systematically searched for articles, on BR communication and visual formats for 
risk communication, published after the year 2000 on Scopus up until February 2014, PubMed, 
Web of Science and PsycINFO (details of search terms see supplemental material). The reference 
list of articles that met our inclusion criteria were screened for relevant publications.  In addition we 
included related materials that were known to us at the time from the PROTECT BR group case 
studies, other initiatives, scientific conferences, and websites on the internet.  
One reviewer (CEH) examined titles and abstracts of identified articles. Relevant 
articles were obtained in full, and assessed against the inclusion and study quality criteria described 
below. 
Furthermore we identified visual formats linked to BR methodologies from a recent 
review,2 and highlight prominent visual formats associated with each method. 
Inclusion criteria and data extraction 
We included articles that present or discuss one or more visual formats to 
communicate benefit or risk information, or information in connection to BR assessment. From 
each relevant article we extracted examples of the visual formats presented or discussed, and also 
any relevant discussion and comment on the strengths and weaknesses of the visual format.  
Appraisal criteria and strategy 
We identified distinct types of visual formats from the literature and grouped them 
into generic types. The visual types were appraised at group level initially. We made some 
comments on special cases or variation of the visual types where necessary. 
We apprised each group of visual type against five criteria:  intended audience, 
intended message, knowledge required to understand the visuals, unintentional message that may be 
associated with the visuals, and any missing information from the visuals that may be needed to 
understand them (appraisal criteria description see supplemental).   
Since we were not able to formally test individual’s comprehension, we approached 
the appraisal process theoretically  based two sets of principles for visual display design:  Wickens’ 
Principles of Display Design15 and Cleveland’s elementary perceptual tasks.16, 17  
We framed our recommendation of visual formats to be used in medical BR 
communication and representation through nine key BR questions.  The key BR questions were 
adapted from the work of the Communities and Local Government (CLG)  on visual representation 
of data in the public sector, as appeared on the CLG DataViz website7.  
Results 
Searches identified 4,855 potentially relevant articles from the scientific literature. 
Following title and abstract screening, more than 500 were scrutinized in full-text and of those, 55 
were deemed eligible16, 18-71 14 additional sources for visuals were identified including (websites, 
reports).4, 7-14, 72-76 From the 55 identified articles and the 14 additional sources we extracted 66 
examples of visual formats (details of search see supplementing material). In addition we extracted 
additional 33 examples of visual formats associated directly with BR methodologies identified in a 
separate literature review of BR methodologies.2 In table 1 the visual types that are connected to 
specific BR assessment methodologies are presented.   
[INSERT TABLE 1 HERE] 
The extracted visual formats were classified into 13 visual types, of which several include sub-
groups of the variations with specific properties and ways of presentation (see table 2). The 
classifications were based on the well-accepted terminologies of the visual formats from our past 
experience.  
[INSERT TABLE 2 HERE] 
In table 3 we present a selection of visual formats that have more specific use in data 
representation and therefore may be more unfamiliar to lay readers. This is to give a rough idea of 
how an unfamiliar visual format might look. The examples in table 3 include specialist visual 
formats aimed at general audiences, such as a value tree, a risk scale, and a pictogram. These also 
include three variations of bar charts communicating specific information in specific structures 
(waterfall plot, difference display, tornado diagram), and visual formats that communicate statistical 
information such as the box plot and forest plot. A dot chart is also shown, which is a part of a 
forest plot (middle part to show the values of any point estimates). The forest plot is sometimes 
referred to as a “range” graph. 
[INSERT TABLE 3 HERE] 
 
To facilitate the recommendations from this review, we adapted the CLG DataViz’s 
common questions on visual data representation in the public sector to the BR scenario.7 The nine 
adapted BR questions are shown in table 4. 
[INSERT TABLE 4 HERE] 
We found that several visual formats could be used in each of the pre-specified BR questions, depending on the exact message to be 
communicated and to whom different visuals could be relevant.  Table 4: Adaptation of CLG DataViz’s data exploration question to 
BR questions 
CLG questions Adaptation to BR assessment 
How to compare data? How to represent the (raw) magnitudes of quantitative data such as the probabilities 
of events to describe data and to put them into context? 
How to represent the magnitude of the final BR metrics to allow easy comparison of 
the BR balance to be made? 
 
What is changing over time? How to represent how the magnitude of a measure is changing against a range of 
another measure such as time or a range of preference values? 
What is the distribution of an indicator 
variable? 
How to visualise the distributions or uncertainty of safety and efficacy data, 
preferences or a BR metric? 
What are the components of an indicator 
variable? 
How to represent the contributions from the different criteria (components) in a BR 
analysis to allow better perception of the key drivers? 
What is the relationship between indicator 
variables? 
How to represent the strength of the relationships between benefit and risk metrics, 
for example to visualise many data points such as patient-level data or to visualise 
the extent of correlation between criteria? 
How significant are the differences? How to represent the degree of statistical significance in the difference between 
alternatives? 
How to visualise qualitative data? How to represent and present qualitative data such as text descriptions meaningfully 
and simply to support judgment without introducing extra cognitive burden? 
How to visualise categorical data? How to represent categorical data such as groups of patients, discrete events, and 
categorical value function without distorting the data they are presenting? 
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Table 5 gives an overview of which visual formats have the potential to be used in connection to the 
common BR questions. This is shown together with the information of level of expertise that is 
considered to be required to interpret the visual format, and how the visual formats are ranked 
according to Cleveland’s elementary perceptual tasks.16 For a more in-depth description of the 
appraisal of each visual type  see supplemental materials or the PROTECT BR review of visual 
formats for the representation of BR assessment of medication Stage 2.77  
[INSERT TABLE 5 HERE]
Effective visual representations of BR information are not limited to only pictorial 
representations, but also include other components of the visual representation. This may result in 
the inclusion of words that are prone to misinterpretation or misleading. There is also a risk of 
potentially presenting insufficient information. Table 6 gives an overview of some issues to be 
considered with visual representation of BR assessments. We also hypothesised (but have not 
tested) that certain visual types may easily be associated with the specific issues, based on the visual 
display examples extracted from the literature.  
[INSERT TABLE 6 HERE] 
Discussion 
This review set out to evaluate the usefulness of different visual types for the 
representation and communication of BR assessment information. There is not one single visual 
type that is consistently superior to others for the communication of BR information to various 
stakeholders 4. This is partly due to the different types of information to be presented and also partly 
due to the differences in an individual’s perception, understanding and preference of visuals.  
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Firstly we want to point out the importance of considering the intended audience for 
the visual communication. Some visuals such as the simpler bar charts may be used for a variety of 
groups from general public to trained experts, while others like the pictogram or the waterfall plot 
may have more targeted users.  As for the intended audience the intended message is a main factor 
in creating visuals. Although different messages can be communicated by a variety of visual types, 
the level of detail that needs to be communicated can influence the choice of visual type e.g. the 
stacked bar chart can be used to communicate how each of the criteria contribute to the overall BR 
balance, but if the contributions from several criteria are similar it can be difficult to discriminate 
their individual contributions; a grouped bar chart might be a better choice. Whether the chosen 
visual representation causes an unintended message, or gives an unjust impression of certainty to 
the presented BR balance should also be considered. Furthermore, one should consider what 
knowledge is required to interpret the visual, and this is often related to technical skills such as 
understanding the logarithmic scale, or medical terms. In addition it is also important to ensure that 
the visual includes all necessary information to correctly interpret and understand the visual. This 
could be as simple as making sure that the axes has the right labelling.  Table 7 outlines four criteria 
for determining audience-visual compatibility. 
[INSERT TABLE 7 HERE] 
In addition to determining audience-visual compatibility when creating visuals for 
communication in BR assessment, we recommend applying Wickens’ Principles of Display 
Design15 and the GlaxoSmithKline Graphics Principles.78 Although these principles were not 
developed specifically for the visual representation of BR assessments in medicine, they do offer 
some advice on the design of general visual representation, which are easily adaptable for our 
purpose.  
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We set out to propose visual types that could be of interest when presenting 
information related to nine central BR questions (see table 4). Here, particularly Cleveland’s 
elementary perceptual tasks have been our focus.16, 17  
 A table can serve as a useful BR communication tool due to its simple structure, 
flexibility and the ease with which it can be adapted. Readability can be enhanced through the use 
of colour-coding to represent grouping and relationships, as done in the BRAT framework .79 For 
tables it is important to be aware that they can be thought of as containing a list, with a long list of 
risks perceived as having unfavourable BR balance without taking into account the actual 
quantitative data of their severity and incidence. The table is suitable for many audiences from 
general public to experts. It communicates well the criteria considered in a BR assessment, their 
hierarchical structure and the statistical summaries associated with the favorable and unfavorable 
effects.The two main examples are the key BR table from BRAT,79 and the effect table from 
PrOACT-URL.72 
Tree diagrams can communicate qualitative information such as which benefits and 
risks are pivotal to the BR balance, and can represent the hierarchy of associations among the 
criteria, as seen with the BRAT.79 Like the table, it is important to be aware of the potential 
downside that an imbalance in the number of benefit and risk criteria can be perceived as an 
unbalanced BR profile without taking into account the actual quantitative data.  
The risk ladder/scale can facilitate comparison and judgment; it often provides 
information on other risks for comparison to particularly assist the general public and patients as 
well as regulators in perceiving the magnitude of risks under discussion.50 For the risk scale it is 
important to make sure that, if used, logarithmic scale in clearly marked, and understood by the 
audience. Risk ladders or scales are designed to ease the communication of risks by anchoring the 
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risks against commonly understood scenarios, however it is important to make sure the anchors are 
understood and relevant to the audience.   
The pictogram has generally proven to be quickly and better comprehended than other 
graphical formats when used to communicating individual statistics,35, 40, 65 and can help to prevent 
patients from being biased by other factors33. Therefore the pictogram is of interest as an easily 
comprehended visual format when communicating to the general public about the relative 
frequencies of favourable effects and the incidence of unfavourable effects. 
The bar chart includes several special cases, where the simple bar chart, 
stacked/divided bar chart and grouped bar chart are the most familiar, the bar chart is usually easy 
to read and interpret.  For the stacked bar chart one should be aware that it can be more difficult to 
rank order the categories than for the grouped bar chart. Bar charts often best represent categorical 
data; they only have one value axis, whilst the other axis represents discrete categories such as 
groups. The simpler bar charts (simple bar chart, stacked bar chart and the grouped bar chart) could 
be suitable for a large variety of audiences such as the general public through the media, patients, 
physicians, regulators and other experts for communication about the final BR metric and to 
visualise the contributions of the different criteria (components) in the BR analysis, and to visualise 
categorical data.  Special cases of the bar chart include the tornado diagram, the difference display 
and the waterfall diagram; (see table 3). The special cases have many of the same features as the 
simpler bar charts, but will general require more explanation to be clearly understood. The 
difference display is relevant to represent, for a trained audience, the contributions of the different 
criteria in the BR analysis, and was also recommended as a visual for displaying results of BR 
analysis in the recent report from EMA BR methodology project.72 The tornado diagram is 
proposed for the communication of uncertainty of the BR metric and visualise the relationships 
between benefit and risk metrics and correlated criteria, again for a trained audience.  Finally, the 
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waterfall plot can be used to communicate about how benefits increase as more favourable effects 
are considered, and then successively reduce as the unfavourable effects are included. 
The dot plot has similar features compared to the simple bar chart, and offers a very 
high data-ink ratio.67 The forest plot is a special case of dot plot, which contains more statistical 
underpinnings and can be used to represent summary measures such as mean risk difference and 
risk ratios as well as their associated uncertainty via confidence intervals, as in BRAT79 and is most 
suitable to a specialist audience such as physicians, the regulators and other experts. 
Line graphs communicate the relationship of changes in one measure such as 
frequency or probability of an event over a range of values in another effect – time, dose levels etc. 
A line graph is a very common type of visual display many people come across in various media 
such as in the newspaper or on television (e.g. stock values line graph, trends in historical weather 
or the forecast etc.). Although general awareness may not be the best measure of broad applicability 
of visual understanding in BR assessment, such exposure to line graphs may make them suitable for 
communication to most people.  
Scatter plots allow users to perceive the strength of relationship between any two 
uncertain quantities, and can also reflect the variability in the data. Scatter plots are fairly intuitive 
and do not need any specialised knowledge in order to understand them.  
Box plots (also known as the box and whiskers diagram) are used to convey statistical 
information by presenting a summary of the dataset in terms of their position in the data. The box 
plot can be used to represent the distributions of uncertainty for efficacy and safety data. Due to the 
technical constructions of box plot, they may be limited to experts or trained audience who have 
some understanding on statistical summary measures such as medians, means, quartiles, outliers 
etc.  
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The area graphs and volume charts suffer from people’s ability to perceive area and 
volume differently.16 In the case of volume chart, it becomes worse because of our limitation to 
accurately judge the size of three-dimensional objects. The only area graph we find of interest is the 
distribution plot, which may look like a line graph but the information is actually being 
communicated by the area under the curve. The distribution plot is a well know way to of 
representing data distributions for experts or a trained audience who have some understanding on 
statistics. It can be used to represent the distribution or uncertainty of a measure; showing the 
patient-level distribution of data and to communicate about the statistical significance in the 
difference between alternatives, to an expert audience.  
Cartoons/icons or pictograms can be used to indicate if something is a positive or a 
negative outcome, inform about specific patient groups (e.g., men or women), and indicate the 
direction of a change. Pictograms or cartoons have the potential to cross the language barrier and 
would be particularly useful for people who are sighted or partially-sighted but are unable to read. It 
is important that pictograms, cartoons, icons or symbols used in BR visual representations are 
recognisable images which the intended users would have had experience seeing in the past to 
support their understanding.15 Cultural differences may be the most prohibitive when it comes to 
cartoons, icons and symbols because the images may not be common or could even be offending to 
some cultures. 
The pie chart is an often a widely used visual, however the reading of angles means 
that it scores fairly low on Cleveland’s elementary perceptual task scale and it is difficult to rank 
order categories and compare between pie charts.16 
Statistical maps in the form of geographical maps may not be very relevant for use in 
the BR assessment. A different type of statistical map is the “sector map”, it is used as a type of 
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graphical method to detect and display differences in adverse event rates between treatment groups. 
The sector map provides a high level overview of the situation, and makes use of colour to encode 
information that can then be drilled down to the required level of details. However, this type of 
representation may be affected by the limitations of area judgment and colour intensity.  
Conclusions 
Our main recommendation for the creation of visuals for BR assessments is to 
determine the compatibility between a visual and its target audience. This is done by considering 
the intended audience for the visual, the main message the visual should communicate, and the 
knowledge required to understand and to extract information from the visual. We specifically 
suggest evaluating whether any message may be missed or any unintended message could be drawn 
from a visual. 
Secondly, we aim to help BR analysis experts and decision-makers to navigate 
through the many visual types using a series of common BR questions. An overview of the key BR 
questions and the visuals proposed is provided in table 8, together with the ease of interpretation for 
each visual format and possible misinterpretation to take in consideration.  
[INSERT TABLE 8 HERE] 
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Table 1: Overview of visual representation connected to BR methodologies 
Approach Visual representation of results Other visual representations of special interest 
PrOACT-URL ‘Effects’ table n/a 
PhRMA BRAT Table, dot/forest plot, bar graph Tree diagram to represent model. 
MCDA Bar graph, ‘difference display’ Table for evidence data, tree diagram to represent model, 
line graph for sensitivity analysis. 
SMAA Bar graph, dot/forest plot Table for evidence data, tree diagram and distribution plot 
to represent model, line graph and scatter plot for 
sensitivity analysis. 
BRR Bar graph, dot/forest plot, line graph Scatter plot or contour plot for sensitivity analysis. 
Tornado diagram may be suitable to simplify further the 
results. 
NNT/NNH Dot/Forest plot, line graph, scatter plot Contour plot for sensitivity analysis. Tornado diagram may 
be suitable to simplify further the results. 
INHB Line graph, scatter plot Contour plot for sensitivity analysis. 
Impact Numbers Dot/Forest plot, line graph, scatter plot Contour plot for sensitivity analysis. Tornado diagram may 
be suitable to simplify further the results. 
QALY Bar graph, dot/forest plot Line graph or scatter plot for sensitivity analysis. 
Q-TWiST Bar graph, dot/forest plot Line graph or scatter plot for sensitivity analysis. 
PSM n/a Network graph to represent model. 
MTC n/a Network graph to represent model. 
DCE Bar graph Line graph or scatter plot for sensitivity analysis. 
PrOACT-URL (Problem, Objective, Alternative, Consequence, Trade-off – Uncertainty, Risk tolerance, Linked decisions), 
PhRMA BRAT (Pharmaceutical Research and Manufacturers of America  Benefit-risk Action Team), MCDA (Multi-criteria 
decision analysis), SMAA (Stochastic Multi-criteria Acceptability Analysis ), BRR (Benefit-Risk Ratio), INHB (Incremental Net 
Health Benefit), NNT/NNH (Numbers Needed to Treat/Numbers Needed to Harm), QALY (Quality Adjusted Life Years), Q-
TWiST (Quality adjusted Time Without Symptoms and Toxicity), PSM (Probabilistic Simulation Method), MTC (Mixed 
Treatment Comparison) and DCE (Discrete Choice Experiment). 
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Table 2: Visual types and visual type sub-groups 
 
 
Visual type Sub-group Reference 
Area graphs Area graph  16, 23, 38, 46, 58, 67, 76 
 Distributions plots 14, 67 
 Volume graphs 46, 67 
 Frontier graph 53 
Bar chart Simple bar chart 16, 22, 23, 29, 35, 40, 46, 49, 50, 59, 62, 67 
 Grouped bar chart 16, 24, 32, 40, 46, 50, 54, 59, 64, 66, 67, 69 
 Divided/stacked bar chart 16, 23, 25, 28-30, 33, 37, 39, 46, 47, 54, 67-71, 73 
 Difference diagram 72 
 Tornado diagram  
 Waterfall plots  
Box plot  28, 34, 46, 50, 56, 67 
Cartoons, symbols and icons  21, 46, 50, 52, 55, 64, 67, 74, 80 
Dot chart Dot chart 16, 28, 40, 46, 67 
 Forest plot 20, 68, 73, 81 
Line graphs Line graph 16, 22-24, 28, 35, 46, 50, 54, 60, 66, 67 
 Frontier area graph 17 
Maps Statistical maps 16, 22, 31, 67 
 Sector maps (tree map)  
Pictograms  
18, 22, 23, 25, 30-33, 35, 36, 40-42, 44, 47, 50, 52, 
54, 57, 59, 60, 65, 67, 70, 71, 80 
Pie charts Pie charts 16, 22, 23, 28, 35, 40, 46, 50, 63, 67, 71 
 Nightingale rose 50 
 Speedometer 52 
Risk scales/ladder  18, 22, 26, 32, 45, 48, 49, 61, 64, 65 
Scatter plot  16, 28, 46, 66, 67 
Tables  23, 30, 38, 40, 46, 65, 67 
Tree diagram Tree diagram 30, 38, 47 
 Value tree 81 
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Table 3: Examples of selected visual formatsa, from the top left, the value tree, the risk scale, a pictogram, a waterfall plot, a 
difference display, a tornado diagram, a box plot, a dot plot and in the bottom right corner a forest plot. 
Value tree 
 
 
Risk scale 
 
Pictogram 
  
Waterfall plot (bar chart) 
 
Difference display (bar chart)
 
Tornado diagram (bar chart)
 
Box plot 
 
Dot plot 
 
Forest plot  
 
                                                 
a For more examples see supplementing material or www.imi-protect.eu/benefit-risk 
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Table 4: Adaptation of CLG DataViz’s data exploration question to BR questions 
CLG questions Adaptation to BR assessment 
How to compare data? How to represent the (raw) magnitudes of quantitative data such as the probabilities 
of events to describe data and to put them into context? 
How to represent the magnitude of the final BR metrics to allow easy comparison of 
the BR balance to be made? 
 
What is changing over time? How to represent how the magnitude of a measure is changing against a range of 
another measure such as time or a range of preference values? 
What is the distribution of an indicator 
variable? 
How to visualise the distributions or uncertainty of safety and efficacy data, 
preferences or a BR metric? 
What are the components of an indicator 
variable? 
How to represent the contributions from the different criteria (components) in a BR 
analysis to allow better perception of the key drivers? 
What is the relationship between indicator 
variables? 
How to represent the strength of the relationships between benefit and risk metrics, 
for example to visualise many data points such as patient-level data or to visualise 
the extent of correlation between criteria? 
How significant are the differences? How to represent the degree of statistical significance in the difference between 
alternatives? 
How to visualise qualitative data? How to represent and present qualitative data such as text descriptions meaningfully 
and simply to support judgment without introducing extra cognitive burden? 
How to visualise categorical data? How to represent categorical data such as groups of patients, discrete events, and 
categorical value function without distorting the data they are presenting? 
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Table 5: Information on the level of expertise required for interpreting visual types, the rank of visuals according to Cleveland’s elementary perceptual tasks, and the visual types ability 
to communicate messages connected to the central BR questions, as indicated by an “x”.  
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Level of expertise required E E E E E E E E E E E E E M M M M M M M D D D D 
Rank at elementary perceptual task (1-7) - - - - - 1 1 1 1 1 5 6 6 1 1 1 2 2 3 5 3 3 3 5 
Represent magnitudes of measures and ease comparison   x x  x x x x x x x x x  x x x x    x x 
Represent change in a magnitude of a measure over the 
range of another measure 
       x x    
 
 x x     x x 
x 
 
Represent the distribution or uncertainty of a measure              x  x x   x  x x  
Represent contributions from different criteria to BR       x        x    x  x    
Represent the strength of relationships between measures                 x     x   
Represent degree of statistical significance               x  x    x     
Represent qualitative data x x x x x                    
Represent categorical data    x  x x     x   x x   x  x    
E (easy) – no or very little expertise required of the users to understand the visuals presented. Accessible to patients, general public and suitable for mass media communication. The 
visual may be presented to user without much explanation 
M (intermediate) – some experience with straightforward BR assessment methodology may be required of the users in is not necessary to understand the theoretical foundation of the 
model. Accessible to practicing physicians and patients representatives who need to understand and communicate BR to patients, care givers or general public. The visuals may be 
presented to users without much explanation but would benefit from annotations or experts’ explanation.  
D (difficult) – Some experience and familiarity with complex BR assessment methodology, decision analysis and statistics may be required to fully exploit and understand these visuals. 
Accessible to BR experts in regulatory agencies, pharmaceutical companies, academia, and are suitable for specialist publication only for making high-level decisions. The visuals may 
also benefit from clear annotations and labelling to avoid presenting misleading information. 
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Table 6: Overview of potential risk of misinterpretation related to visual communication. The right column states which visual 
formats that are specific related to a problem, this however does not mean that the problem should not be considered in connection to 
other visual formats. 
Issue Description Examples of visual types 
related to the issue 
Verbal labels   
 Gradable adjectives Adjectives are easy and natural to be used in the presentation of BR 
assessment and may better capture a person’s emotions and intuitions,25, 
49 and can have the ability to put a treatment into context. Examples of 
gradable adjectives are “high risk”, “very high risk” etc. 
Risk of misinterpretation is especially high if verbal  labels are not 
accompanied by numerical representation.60 
Risk scales 
 Technical terms This could be medical or statistical terms that are not understood by an 
untrained audience. Examples of technical terms are confidence intervals, 
densities, utilities, cardiovascular events. 
Any visual type 
Numerical representation It is important to be consistent in the use of numerical format when 
making comparison 49  
There is a general consensus that relative frequencies are superior to 
percentages or probabilities for a transparent communication of risk 
information. 25, 33, 38, 49 
Any visual type 
 Relative risk (RR) A relative risk is a ratio of two incidence rates. RR may lead people to 
systematically underestimate or overestimate treatment effects, 
depending on the effect size.26, 33, 38 
RR does not, on its own, provide all the necessary information to the 
audience since it is relative to a measurement that might be unknown to 
the audience.38 
Forest plot 
Denominator neglect An example of denominator neglect is the arbitrary and inconsistent use 
of denominators when describing frequencies in different situations. For 
example a frequency of a unfavourable effect of one in five (1:5) may be 
perceived as safer than a frequency of a unfavourable effect of 20 in a 
hundred (20:100), although they are exactly the same.25, 50, 54, 60 
Pictograms 
Numerical representation 
as frequencies 
Logarithmic scales When visuals presenting logarithmic scales are not clearly labelled, they 
can cause users to perceive consecutive risks as being additive rather than 
multiplicative, e.g. reducing a probability with 1 in 10 to 1 in 100 may be 
perceived as being the same as reducing a probability with 1 in 100 to 1 
in 1000. 
Risk scales 30 (which in 
often used for an 
untrained audience) 
Forest plot showing 
relative risks or odds 
ratios. 
Missing part-to-whole 
information 
Emphasizes the foreground information without sufficient background 
could lead to a misperception of the difference in the measures such as 
the probabilities between two events.18 
Bar charts 
Pictograms 
Dot charts 
Area/volume graphs 
Abundance of events 
  
A long list of risks for a drug in comparison to short list of benefits, for 
example, may be perceived as an unfavourable BR balance without 
taking into account the actual quantitative data. 
Tables 
Tree-diagrams 
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Table 7: Criteria to determine audience-visual compatibility prior to generating visuals 
1. Intended audience. Specify the intended main audience/user and verify whether the final visual 
is still suitable for the initially intended group of audience. 
 The main user(s) of the visual could be the general public/media, patient, prescriber, regulator or expert 
(medical, statistical, decision analyst). If the visual is intended for more than one group of users, 
consider criteria 2-4 below for each group. 
2. Message. Specify the main message of the visual, and verify that the final visual still 
communicates the intended message clearly; and that it is free from unintentionally misleading or 
confusing information. 
 The main intended message could be information about the BR balance, input data, probability of an 
event, uncertainty related to input data or BR, sensitivity of the benefit risk analysis, integrated BR 
balance, the BR process, etc.  
 Unintentional misleading/confusing message could be due to the visual display design itself, or the lack 
of user’s knowledge that was not anticipated in the design stage. Unintentional messages could be 
incoherent reflection of the original data, any misleading assurance of the BR balance, the amount of 
certainty/uncertainty of the BR balance are not presented sufficiently, etc. 
3. Knowledge required. Specify the expected level of knowledge required to understand and to 
extract information from the visual. Verify that the final visual is at an appropriate level for the 
intended group of audience. 
 Knowledge requirement could be any technical skills (e.g. understanding of logarithmic scale, concepts 
used in descriptive statistics), any medical knowledge (e.g. severity of condition, reversible 
effects/events, passing events, and conditional relationships), and any background information about the 
measures in the visual (e.g. population affected). Ensure that the required knowledge is easily 
accessible by the users. 
4. Message not communicated. For all of the above, verify in the final visual that there are 
sufficient representations of the information for the intended message to be communicated and 
understood clearly. 
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Table 8: Overview of visual representations recommended for further consideration 
Key BR question Visual format Ease of 
interpretation 
Possible misinterpretations 
To represent the comparison of the magnitudes of 
the final BR metrics e.g. scores or expected utilities 
between alternatives. 
Simple bar graph Easy Effects can be emphasised  by not showing part-to whole 
information 
Stacked bar graph Easy Effects can be emphasised  by not showing part-to whole 
information 
Difficult to compare the categories across options 
Risk of misinterpretation by reading of the values 
corresponding to height of the bar section instead of the actual 
length 
To represent the comparison of the magnitudes of 
quantitative data e.g. probabilities of events 
 
 
 
 
 
 
 
 
 
 
 
Table – ‘Effects table’, 
‘source table’ 
Easy Incorrectly perceived as list, could give a false impression on 
BR balance 
Hierarchies may be perceived when reading a table since 
information appears by lines, and could be read as such 
Risk scales/ladder – 
‘Community risk scale’ 
Easy Risk of unclear rational for risks chosen as anchors for 
comparison. 
Inaccurate and inconsistent interpretation of logarithmic 
scales.  
Pictogram/ pictograph/ 
icon array 
Easy Risk of misinterpretation when different  total number of 
icons (numerator) are used in a series of pictograms 
The absolute number of icons can influence the perceived 
likelihood 
The pictograms do not represent the entire population 
Partial displayed figures tend to be rounded up in 
interpretation 
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Key BR question Visual format Ease of 
interpretation 
Possible misinterpretations 
To represent how the magnitude of a measure is 
changing against a range of another measure e.g. 
time, preference values. 
Line graph Easy Difficult to estimate the vertical difference between two 
curves on the same graph 
Misleading when they are used to represent ranks, nominal or 
ordinal measures 
Dot chart/ forest plot Easy  
Waterfall plot (bar chart) Difficult Risk of misinterpretation since a bar begins where the above 
bar end. 
To represent the distributions or uncertainty of 
efficacy or safety data or a BR metric. 
Distribution plot (area 
graph) 
Difficult Difficult to judge the size of a difference between two areas 
Forest plot Intermediate Confidence intervals around the point estimates can cause 
attention to the criteria with larger confidence interval 
Tornado diagram Difficult  
Box plot Intermediate Require statistical knowledge 
To represent the contributions of the different 
criteria (categories) in the BR analysis. 
 
 
 
 
 
Stacked bar graph Intermediate Effects can be emphasised  by not showing part-to whole 
information 
Difficult to compare the categories across options 
Risk of misinterpretation by reading of the values 
corresponding to height of the bar section instead of the actual 
length 
Difference display (bar 
graph) 
Intermediate Small differences can disappear compared to larger 
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Key BR question Visual format Ease of 
interpretation 
Possible misinterpretations 
To represent the contributions of the different 
criteria (categories) in the BR analysis. (continued)  
Grouped bar graph Intermediate Effects can be emphasised  by not showing part-to whole 
information 
To represent the strength of relationships between 
benefit and risk metrics e.g. for many data points 
like patient-level data or correlated criteria. 
Scatter plot Intermediate Overlapping points cannot be distinguished 
Could draw attention to relationship in data that are not 
clinical relevant 
Nominal scales can be misunderstood to have same 
interpretation as the continuous scale 
Tornado diagram Difficult  
To represent the statistical significance in the 
difference between alternatives. 
Distribution plot (area 
graph) 
Intermediate Difficult to judge the size of a difference between two areas 
Forest plot Intermediate Confidence intervals around the point estimates can cause 
attention to the criteria with larger confidence interval 
To represent and present qualitative data e.g. text 
descriptions.  
 
 
 
 
 
 
 
 
Table Easy Incorrectly perceived as list, could give a false impression on 
BR balance 
Hierarchies may be perceived when reading a table since 
information appears by lines, and could be read as such 
Tree diagram Easy Risk of misinterpreting the value tree if overweight of benefit 
or risk criteria to represent BR balance 
Cartoons/ icons Easy Misunderstanding due to  cultural differences 
Imprecise information 
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Key BR question Visual format Ease of 
interpretation 
Possible misinterpretations 
To represent categorical data e.g. groups, discrete 
events, categorical value function. 
Simple bar graph Easy Effects can be emphasised  by not showing part-to whole 
information 
Grouped bar graph Easy Effects can be emphasised  by not showing part-to whole 
information 
Dot plot Easy Risk of falsely perceiving relationship or variability in data 
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